Insulet Corp (PODD)

33.87
0.92 2.60
NASDAQ : Health Care
Prev Close 34.79
Open 34.89
Day Low/High 33.87 / 34.94
52 Wk Low/High 23.94 / 40.21
Volume 111.31K
Avg Volume 676.40K
Exchange NASDAQ
Shares Outstanding 57.16M
Market Cap 1.96B
EPS -1.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

New Data Demonstrate Benefits Of Insulet's Omnipod® System For People With Type 1 And Type 2 Diabetes

New Data Demonstrate Benefits Of Insulet's Omnipod® System For People With Type 1 And Type 2 Diabetes

Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its Omnipod Insulin Management System (Omnipod System), today announced two online publications of new data in the Journal of...

Insulet Partners With Joslin Diabetes Center To Implement A Unique Training Certification For Insulet's Clinical Team

Insulet Partners With Joslin Diabetes Center To Implement A Unique Training Certification For Insulet's Clinical Team

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced that almost 100 members of Insulet's...

Insulet To Present Omnipod® Clinical Studies On Type 1 And Type 2 Diabetes During The American Diabetes Association's 76th Scientific Sessions

Insulet To Present Omnipod® Clinical Studies On Type 1 And Type 2 Diabetes During The American Diabetes Association's 76th Scientific Sessions

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System (Omnipod System), today announced new clinical data...

Insider Trading Alert - PODD, POWI And SNSS Traded By Insiders

Insider Trading Alert - PODD, POWI And SNSS Traded By Insiders

Stocks with insider trader activity include PODD, POWI and SNSS

Insulet Launches New Omnipod® Podder™ Community Platform

Insulet Launches New Omnipod® Podder™ Community Platform

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System (Omnipod System), today announced the launch of a new...

Insulet (PODD) Is Strong On High Volume Today

Insulet (PODD) Is Strong On High Volume Today

Trade-Ideas LLC identified Insulet (PODD) as a strong on high relative volume candidate

On Tap for Analysts: Boston Scientific, Ford, Western Digital

On Tap for Analysts: Boston Scientific, Ford, Western Digital

Here are Friday's top research calls, including downgrades for Ford, Synaptics and Western Digital, and an upgrade for Boston Scientific.

Short Interest In Insulet Increases 15.2%

Short Interest In Insulet Increases 15.2%

The most recent short interest data has been released by the NASDAQ for the 03/15/2016 settlement date, which shows a 705,381 share increase in total short interest for Insulet Corp , to 5,359,798, an increase of 15.16% since 02/29/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Insulet Names Aiman Abdel-Malek, Ph.D. Senior Vice President Of Advanced Technology And Engineering

Insulet Names Aiman Abdel-Malek, Ph.D. Senior Vice President Of Advanced Technology And Engineering

Experienced Senior Executive with Proven Record Leading Global R&D Teams

Insider Trading Alert - PBCT, PODD And SPH Traded By Insiders

Insider Trading Alert - PBCT, PODD And SPH Traded By Insiders

Stocks with insider trader activity include PBCT, PODD and SPH

Insider Trading Alert - PODD, AME And LDL Traded By Insiders

Insider Trading Alert - PODD, AME And LDL Traded By Insiders

Stocks with insider trader activity include PODD, AME and LDL

Insulet Announces Organizational Enhancements

Insulet Announces Organizational Enhancements

Shacey Petrovic Promoted to President, Insulet Diabetes Products

Insulet Announces Development Partner For The OmniPod Artificial Pancreas

Insulet Announces Development Partner For The OmniPod Artificial Pancreas

Company's Alliance with Algorithm Partner Marks Critical Step Forward in Advanced Diabetes Treatment

Insulet Appoints David A. Lemoine To Board Of Directors

Insulet Appoints David A. Lemoine To Board Of Directors

New Independent Director Brings Extensive Accounting and Financial Reporting Expertise

Insulet To Divest Neighborhood Diabetes Supplies Business

Insulet To Divest Neighborhood Diabetes Supplies Business

Signs definitive agreement to sell Neighborhood Diabetes to Liberty Medical

Insulet Raises Funds For Continued Diabetes Research

Insulet Raises Funds For Continued Diabetes Research

Company Fund-Raising Program Results in a $10,000 donation each to the ADA and JDRF

PODD: Insiders vs. Shorts

PODD: Insiders vs. Shorts

The most recent short interest data was recently released by the NASDAQ for the 10/30/2015 settlement date, and Insulet Corp is one of the most shorted stocks of the Russell 3000, based on 14.27 "days to cover" versus the median component at 5.62. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Insulet Corporation Recognizes National Diabetes Awareness Month At NASDAQ Stock Market Opening Bell Ceremony

Insulet Corporation Recognizes National Diabetes Awareness Month At NASDAQ Stock Market Opening Bell Ceremony

Patrick Sullivan, Insulet's President and Chief Executive Officer, highlights the benefits of Insulet's OmniPod® System for diabetes management

First Week of October 16th Options Trading For Insulet (PODD)

First Week of October 16th Options Trading For Insulet (PODD)

Investors in Insulet Corp saw new options begin trading this week, for the October 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PODD options chain for the new October 16th contracts and identified the following call contract of particular interest.